Ishares Biotechnology Etf Price Prediction
| IBB Etf | USD 136.10 1.26 0.93% |
Oversold Vs Overbought
63
Oversold | Overbought |
Using IShares Biotechnology hype-based prediction, you can estimate the value of iShares Biotechnology ETF from the perspective of IShares Biotechnology response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in IShares Biotechnology to buy its etf at a price that has no basis in reality. In that case, they are not buying IShares because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell etfs at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
IShares Biotechnology after-hype prediction price | USD 135.99 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as etf price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
IShares |
IShares Biotechnology After-Hype Price Prediction Density Analysis
As far as predicting the price of IShares Biotechnology at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in IShares Biotechnology or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Etf prices, such as prices of IShares Biotechnology, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
IShares Biotechnology Estimiated After-Hype Price Volatility
In the context of predicting IShares Biotechnology's etf value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on IShares Biotechnology's historical news coverage. IShares Biotechnology's after-hype downside and upside margins for the prediction period are 134.87 and 137.11, respectively. We have considered IShares Biotechnology's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
IShares Biotechnology is very steady at this time. Analysis and calculation of next after-hype price of iShares Biotechnology ETF is based on 3 months time horizon.
IShares Biotechnology Etf Price Prediction Analysis
Have you ever been surprised when a price of a ETF such as IShares Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading IShares Biotechnology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Etf price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with IShares Biotechnology, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.12 | 1.13 | 0.11 | 0.00 | 7 Events / Month | 3 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
136.10 | 135.99 | 0.08 |
|
IShares Biotechnology Hype Timeline
On the 22nd of November iShares Biotechnology ETF is traded for 136.10. The entity has historical hype elasticity of -0.11, and average elasticity to hype of competition of 0.0. IShares is forecasted to decline in value after the next headline, with the price expected to drop to 135.99. The average volatility of media hype impact on the company price is about 118.95%. The price depreciation on the next news is expected to be -0.08%, whereas the daily expected return is currently at -0.12%. The volatility of related hype on IShares Biotechnology is about 7264.29%, with the expected price after the next announcement by competition of 136.10. The company recorded a loss per share of 11.38. Considering the 90-day investment horizon the next forecasted press release will be in about 7 days. Check out IShares Biotechnology Basic Forecasting Models to cross-verify your projections.IShares Biotechnology Related Hype Analysis
Having access to credible news sources related to IShares Biotechnology's direct competition is more important than ever and may enhance your ability to predict IShares Biotechnology's future price movements. Getting to know how IShares Biotechnology's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how IShares Biotechnology may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MDEV | First Trust Exchange Traded | 0.09 | 3 per month | 0.00 | (0.13) | 1.37 | (1.04) | 3.02 | |
| MEDX | Horizon Kinetics Medical | 0.00 | 0 per month | 0.00 | (0.40) | 0.89 | (1.65) | 4.42 | |
| MEDI | Harbor Health Care | (0.30) | 2 per month | 0.00 | (0.20) | 1.25 | (1.69) | 5.09 | |
| FHLC | Fidelity MSCI Health | (0.67) | 3 per month | 0.00 | (0.29) | 0.83 | (1.17) | 3.13 | |
| BBC | Virtus LifeSci Biotech | 0.49 | 5 per month | 0.00 | (0.07) | 3.40 | (3.53) | 10.41 | |
| BBH | VanEck Biotech ETF | 0.36 | 1 per month | 0.00 | (0.28) | 1.16 | (1.87) | 6.02 | |
| BBP | Virtus LifeSci Biotech | 0.49 | 1 per month | 0.00 | (0.09) | 1.79 | (2.73) | 6.06 | |
| BIB | ProShares Ultra Nasdaq | (0.69) | 2 per month | 0.00 | (0.17) | 2.60 | (3.95) | 12.63 | |
| BIS | ProShares UltraShort Nasdaq | 0.09 | 9 per month | 1.37 | 0.1 | 4.25 | (2.63) | 9.62 |
IShares Biotechnology Additional Predictive Modules
Most predictive techniques to examine IShares price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for IShares using various technical indicators. When you analyze IShares charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About IShares Biotechnology Predictive Indicators
The successful prediction of IShares Biotechnology stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as iShares Biotechnology ETF, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of IShares Biotechnology based on analysis of IShares Biotechnology hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to IShares Biotechnology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to IShares Biotechnology's related companies.
Story Coverage note for IShares Biotechnology
The number of cover stories for IShares Biotechnology depends on current market conditions and IShares Biotechnology's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that IShares Biotechnology is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about IShares Biotechnology's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Check out IShares Biotechnology Basic Forecasting Models to cross-verify your projections. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
The market value of iShares Biotechnology ETF is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is IShares Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Biotechnology's market value can be influenced by many factors that don't directly affect IShares Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.